Generation Bio Future Growth
Future criteria checks 0/6
Generation Bio's revenue is forecast to decline at 15.6% per annum while its annual earnings are expected to grow at 11.5% per year. EPS is expected to grow by 24.1% per annum. Return on equity is forecast to be -19% in 3 years.
Key information
11.5%
Earnings growth rate
24.1%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | -15.6% |
| Future return on equity | -19.0% |
| Analyst coverage | Good |
| Last updated | 20 Nov 2024 |
Recent future growth updates
Recent updates
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Dec 07Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth
Jul 11We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Mar 11Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9 | -80 | N/A | N/A | 5 |
| 12/31/2025 | 7 | -81 | -75 | -71 | 7 |
| 12/31/2024 | 18 | -118 | -53 | -48 | 7 |
| 9/30/2024 | 19 | -145 | -104 | -98 | N/A |
| 6/30/2024 | 13 | -158 | -110 | -103 | N/A |
| 3/31/2024 | 10 | -169 | -65 | -57 | N/A |
| 12/31/2023 | 6 | -127 | -60 | -53 | N/A |
| 9/30/2023 | 3 | -124 | -54 | -51 | N/A |
| 6/30/2023 | 1 | -127 | -50 | -46 | N/A |
| 3/31/2023 | N/A | -134 | -101 | -95 | N/A |
| 12/31/2022 | N/A | -137 | -111 | -102 | N/A |
| 9/30/2022 | N/A | -135 | -111 | -100 | N/A |
| 6/30/2022 | N/A | -136 | -114 | -102 | N/A |
| 3/31/2022 | N/A | -129 | -112 | -104 | N/A |
| 12/31/2021 | N/A | -119 | -98 | -92 | N/A |
| 9/30/2021 | N/A | -112 | -94 | -89 | N/A |
| 6/30/2021 | N/A | -101 | -91 | -85 | N/A |
| 3/31/2021 | N/A | -88 | -80 | -75 | N/A |
| 12/31/2020 | N/A | -81 | -76 | -70 | N/A |
| 9/30/2020 | N/A | -72 | -68 | -64 | N/A |
| 6/30/2020 | N/A | -68 | -66 | -57 | N/A |
| 3/31/2020 | N/A | -65 | -62 | -46 | N/A |
| 12/31/2019 | N/A | -61 | -60 | -40 | N/A |
| 12/31/2018 | 0 | -36 | -31 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GBIO's revenue is expected to decline over the next 3 years (-15.6% per year).
High Growth Revenue: GBIO's revenue is forecast to decline over the next 3 years (-15.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GBIO is forecast to be unprofitable in 3 years.